Takahama M, Tsutsumi M, Tsujiuchi T, Kido A, Okajima E, Nezu K, Tojo T, Kushibe K, Kitamura S, Konishi Y
Department of Oncological Pathology, Nara Medical University, Japan.
Jpn J Clin Oncol. 1998 Mar;28(3):176-81. doi: 10.1093/jjco/28.3.176.
Angiogenesis is an essential factor for progression and metastases in solid tumors. It has been reported that several angiogenic factors play a role in the regulation of angiogenesis. Vascular endothelial growth factor (VEGF) is one of the most important molecules in angiogenesis. We investigated expressions of VEGF in a series of lung carcinomas with regard to clinicopathological factors.
VEGF expression was investigated by use of immunohistochemical studies and Northern blot analysis, using 155 primary and 26 metastatic lung carcinomas for the immunohistochemical studies and 10 primary and two metastatic lung carcinomas for the Northern blot analysis. All lesions were resected at surgery.
The frequencies for positive VEGF expression were 64 of 74 (86.5%) adenocarcinomas, 38 of 67 (56.7%) squamous cell carcinomas, four of four (100%) large cell carcinomas, two of three (66.7%) adenosquamous carcinomas and one of five (20%) small-cell carcinomas, the degree of positivity generally being greater in well differentiated tumors. The majority of metastatic foci from adenocarcinomas and squamous cell carcinomas at other sites were also positive (76.5 and 66.7%, respectively). VEGF expression did not correlate with clinicopathological factors such as tumor size or pathological stage, but pathological stage I adenocarcinoma cases positive for VEGF demonstrated a shorter disease-free period when followed up for 48 months than those cases expressing VEGF negatively.
The results indicated that VEGF expression was frequently detected in non-small-cell lung cancers and suggested that VEGF might relate to the disease-free period of the patients with early adenocarcinomas.
血管生成是实体瘤进展和转移的一个重要因素。据报道，几种血管生成因子在血管生成的调节中发挥作用。血管内皮生长因子（VEGF）是血管生成中最重要的分子之一。我们研究了一系列肺癌中VEGF的表达与临床病理因素的关系。
采用免疫组织化学研究和Northern印迹分析检测VEGF表达，免疫组织化学研究使用155例原发性和26例转移性肺癌，Northern印迹分析使用10例原发性和2例转移性肺癌。所有病变均在手术中切除。
VEGF阳性表达率在腺癌中为74例中的64例（86.5%），在鳞状细胞癌中为67例中的38例（56.7%），在大细胞癌中为4例中的4例（100%），在腺鳞癌中为3例中的2例（66.7%），在小细胞癌中为5例中的1例（20%），通常在高分化肿瘤中阳性程度更高。腺癌和鳞状细胞癌在其他部位的大多数转移灶也呈阳性（分别为76.5%和66.7%）。VEGF表达与肿瘤大小或病理分期等临床病理因素无关，但VEGF阳性的病理I期腺癌病例随访48个月时的无病生存期比VEGF阴性病例短。
结果表明，VEGF表达在非小细胞肺癌中经常被检测到，提示VEGF可能与早期腺癌患者的无病生存期有关。
